Maypharm to Launch New Multi-Active Skin Solution

SEOUL, South Korea – Maypharm, a global aesthetic and cosmeceutical company, announced on September 26, 2026, the upcoming launch of HYALMASS AQUATOX. This new multi-active skin solution is designed to meet the rapidly evolving demands of the global aesthetic market.

Instead of relying on a single trending ingredient, HYALMASS AQUATOX combines five key active ingredients: PDRN, exosomes, botulinum peptide, GHK-Cu, and succinic acid. The company aims to address the growing need for multifunctional cosmetic solutions based on sought-after ingredients.

The product reportedly includes botulinum peptide to promote a smoother and more refined skin appearance, GHK-Cu to support skin conditioning and regeneration, succinic acid for its role in skin revitalization and antioxidant activity, PDRN for skin regeneration and recovery, and exosomes, increasingly recognized for their role in advanced skin rejuvenation approaches.

The launch follows Maypharm's HYALMASS AQUA EXOSOME product line and strengthens the company's presence in the global aesthetic market. The increasing demand for advanced skin rejuvenation products has also led to a rise in offerings with similar ingredient concepts and branding. Maypharm emphasizes the importance of product authenticity and authorized distribution.

With HYALMASS AQUATOX, Maypharm continues to expand its portfolio around emerging aesthetic trends by combining multiple active ingredients into a single product concept. The company urges distributors, aesthetic professionals, and customers to verify the original manufacturer and authorized distribution channel before purchase or use.